Do weight loss peptides specifically target belly fat?

GLP-1 agonists reduce overall body fat, but studies show preferential loss of visceral (belly) fat compared to subcutaneous fat. Retatrutide trials report 30-40% visceral fat reduction. <a href='https://pubmed.ncbi.nlm.nih.gov/35441470/' target='_blank'>Visceral fat study</a>